Antidepressant-relevant concentrations of the ketamine metabolite (2 R ,6 R )-hydroxynorketamine do not block NMDA receptor function
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Significance: Standard antidepressant treatments require weeks to show effectiveness. A single subanesthetic dose of ketamine rapidly attenuates many clinical signs and symptoms of depression; however, ketamine treatment also has many adverse effects, including dissociation and potential for abuse, which are mediated by NMDA glutamate receptor (NMDAR) inhibition. Previous work has revealed that the ketamine metabolite (2 R ,6 R )-hydroxynorketamine (HNK) induces antidepressant-like responses in rodents while minimizing the adverse effects observed with ketamine. The results of this study, using a multitude of experimental approaches, confirm that antidepressant-relevant concentrations of (2 R ,6 R )-HNK are not sufficient to block NMDARs. This provides a basis for work directed at alternative molecular targets and toward novel drugs that exert rapid antidepressant effects independent of NMDAR inhibition and NMDAR-mediated adverse effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“recent research suggests that (R)-ketamine and the ketamine metabolite (2R,6R)-HNK may exert antidepressant-like effects by upregulating AMPAR transmission independent of NMDAR antagonism [30,31].”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [31]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“peak levels of (2R,6R)-HNK in the mouse hippocampus were 7.57 ± 2.13 μM 10 minutes following systemic administration of a dose (10 mg/kg i.p.) that results in antidepressant-like effects in several behavioral tests and returned to near baseline levels by two hours post-administration.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Lumsden et al., 2019
The cited source says what the claim attributes to it.
In the citing paper
“NMDAR blockade does not explain the mechanism of action of (2R,6R)-HNK as its affinity for and functional effects at NMDARs are beyond therapeutically relevant concentrations (Lumsden et al., 2019).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Lumsden et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 3×
“Although there are a multitude of treatment options for depression, typical pharmacotherapies require daily administration over multiple weeks before improvement is expected, with many patients failing to find an effective therapy (3).”
BackgroundInfluentialAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 1×
“Although ketamine is a promising alternative to standard clinically used antidepressants, it induces adverse effects at antidepressant doses, particularly dissociation (10).”
BackgroundmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 2×
“In addition, the possibility cannot be ruled out that immediate changes in mBDNF and mTOR activation occur in a narrow time window following a treatment (34, 35) and may, therefore, have been missed in the earlier study.”
BackgroundResultNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 2×
“In addition, the possibility cannot be ruled out that immediate changes in mBDNF and mTOR activation occur in a narrow time window following a treatment (34, 35) and may, therefore, have been missed in the earlier study.”
BackgroundResultThe anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist.
Wong, E. H., Kemp, J. A., Priestley, T., Knight, A. R., Woodruff, G. N., & Iversen, L. L. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.18.7104 · Cited by 1,819
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Self-citation
Cited by
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
“Ketamine exhibits high affinity for the phencyclidine site of the N-methyl-D-aspartate receptor (NMDAR) (24, 25).”
BackgroundSelf-citationDuman, R. S., Deyama, S., & Fogaça, M. V. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.14630 · Cited by 321
Monoamine Neurotransmitters Control Basic Emotions and Affect Major Depressive Disorders
Jiang, Y., Zou, D., Li, Y., Gu, S., Dong, J., Ma, X., Xu, S., Wang, F., & Huang, J. H. (2022) · Pharmaceuticals · doi:10.3390/ph15101203 · Cited by 253
Self-citationThe role of dissociation in ketamine’s antidepressant effects
Ballard, E. D., & Zarate, C. A. (2020) · Nature Communications · doi:10.1038/s41467-020-20190-4 · Cited by 220
Self-citationStructural basis of ketamine action on human NMDA receptors
Zhang, Y., Ye, F., Zhang, T., Lv, S., Zhou, L., Du, D., Lin, H., Guo, F., Luo, C., & Zhu, S. (2021) · Nature · doi:10.1038/s41586-021-03769-9 · Cited by 218
Metadata
- Authors
- Lumsden, E. W., Troppoli, T. A., Myers, S. J., Zanos, P., Aracava, Y., Kehr, J., Lovett, J., Kim, S., Wang, F.-H., Schmidt, S., Jenne, C. E., Yuan, P., Morris, P. J., Thomas, C. J., Zarate, C. A., Moaddel, R., Traynelis, S. F., Pereira, E. F. R., Thompson, S. M., Albuquerque, E. X., & Gould, T. D.
- Affiliations
- University of Maryland, Baltimore (US)
- Emory University (US)
- Department of Physiology and Pharmacology, Karolinska Institute, SE-171 77 Stockholm, Sweden;
- National Institutes of Health (US)
- Karolinska Institutet (SE)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2019-02-22
- Volume
- 116
- Issue
- 11
- Pages
- 5160-5169
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC6421428
- OpenAlex
- W2917916000
- Cited by
- 158
- References
- 46
- Citations by year
- 2026: 17 · 2025: 17 · 2024: 15 · 2023: 24 · 2022: 19 · 2021: 27 · 2020: 23 · 2019: 16
- FWCI
- 13.17
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- HHS | NIH | National Institute of Mental Health (R01MH107615, R01NS065371)
- Harrington Discovery Institute (NA)
- U.S. Department of Veterans Affairs (1I01BX004062)
- HHS | NIH | National Institute of Neurological Disorders and Stroke (R01NS065371)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine metabolites, (2R,6R)-hydroxynorketamine, NMDA receptor, antidepressant effects, rapid-acting antidepressants, depression, dissociation, ketamine side effects, glutamate receptor antagonism, antidepressant targets
- MeSH terms
- Animals, Antidepressive Agents, Behavior, Animal, Hippocampus, Ketamine, Male, Xenopus laevis, Receptors, N-Methyl-D-Aspartate, N-Methylaspartate, Pyramidal Cells, Excitatory Postsynaptic Potentials, Inhibitory Concentration 50, Protein Subunits, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antidepressant-relevant concentrations of the ketamine metabolite (2 R ,6 R )-hydroxynorketamine do not block NMDA receptor function. https://app.cochat.ai/papers/10.1073/pnas.1816071116
- The paper
- Lumsden, E. W., Troppoli, T. A., Myers, S. J., Zanos, P., Aracava, Y., Kehr, J., Lovett, J., Kim, S., Wang, F.-H., Schmidt, S., Jenne, C. E., Yuan, P., Morris, P. J., Thomas, C. J., Zarate, C. A., Moaddel, R., Traynelis, S. F., Pereira, E. F. R., Thompson, S. M., . . . Gould, T. D. (2019). Antidepressant-relevant concentrations of the ketamine metabolite (2 R ,6 R )-hydroxynorketamine do not block NMDA receptor function. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1816071116
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.